Phase II RAINSPOT: a Multicentric Open Label Trial of Zolbetuximab-Paclitaxel-Ramucirumab in Second Line Setting for CLDN18.2 Positive Gastro-esophageal Adenocarcinoma
Latest Information Update: 15 May 2025
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary) ; Zolbetuximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms RAINSPOT
Most Recent Events
- 15 May 2025 New trial record